IFNAR

Vadimezan (DMXAA) is a vascular disrupting agent, a murine STING agonist, and an inducer of cytokines such as type I IFN. Vadimezan has antitumor activity and induces a rapid cessation of blood flow in tumors without affecting blood flow in normal tissues.

Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor for the treatment of autoimmune diseases. It blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain, inhibiting IL-12 23 and type I IFN pathways. It selectively binds to the TYK2 pseudokinase (JH2) domain with an IC50 of 1.0 nM.

Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NKG2A that induces IFN-γ production, thereby activating natural killer cell function. Monalizumab has antitumor activity and can be used to study neck squamous cell carcinoma (HNSCC).

CCCP (Carbonyl Cyanide m-Chlorophenylhydrazone) is an oxidative phosphorylation (OXPHOS) inhibitor and mitochondrial proton carrier uncoupler. CCCP inhibits the activation of STING and its downstream signaling molecules TBK1 and IRF3.

Anifrolumab(MEDI-546) is a potent type I interferon (IFN) receptor antagonist, a human monoclonal antibody that targets IFN.Anifrolumab inhibits the activity of type I interferon and is used for the prevention and treatment of systemic lupus erythematosus (SLE).

Ginsenoside-F3 has immunoenhancing activity by regulating production and gene expression of type 1, type 2 cytokines in murine spleen cells. Ginsenoside-F3 enhances the NF-kappaB DNA binding activity induced by ConA in murine spleen cells (10 μM).

YE6144 is a prototype IRF5 inhibitor that selectively blocks IRF5 phosphorylation.YE6144 can also inhibit the production of type 1 IFNs (IC50 = 0.09μM).

RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.

AX-024 hydrochloride (AX-024 HCl) is an cytokine release inhibitor which can strongly inhibit the production of interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), interferon-γ (IFN-γ), IL-10 and IL-17A.

Cridanimod (10-carboxymethyl-9-acridanone, CMA) is a potent STING agonist that directly binds to STING and triggers a strong antiviral response through the TBK1 IRF3 route.

IFN alpha-IFNAR-IN-1 hydrochloride is an inhibitor of the interaction between IFN-α and IFNAR, effectively inhibiting MVA-induced IFN-α responses by BM-pDCs with an IC50 of 2-8 μM.

Tilorone dihydrochloride, an orally active interferon inducer, exhibits both antineoplastic and anti-inflammatory actions.

IRF1-IN-1 (Compound I-2) is an IRF1 inhibitor that reduces IRF1 recruitment to the Caspase 1 promoter, inhibiting the cleavage of Caspase 1, GSDMD, IL-1, and PARP1, thereby protecting against skin inflammatory damage.

Interferon receptor inducer-1 Used in the treatment of a disorder in which the induction of interferon is involved. is an interferon (IFN) receptor inducer.

CP-28888 (CP 28888-27) is an interferon inducer, a lipoamine with antitumor activity.

IRF1-IN-2 is a small molecule inhibitor of interferon regulatory factor 1 (IRF1) that functions by reducing the binding affinity of IRF1 for the caspase-1 (CASP1) gene promoter. this inhibition subsequently suppresses critical cell death signaling pathways, such as pyroptosis, and provides robust protection against ionizing radiation-induced skin inflammatory damage in preclinical models.

Dazukibart is a humanized IgG1κ anti-IFNB1 monoclonal antibody of murine origin, being investigated as a potential treatment for dermatomyositis, a complex autoimmune disorder pathologically characterized by the pronounced overexpression of interferon (IFN) inducible genes present within the blood, skin, and muscle tissue of affected patients.

SH514 is a specific IRF4 inhibitor with an IC₅₀ of 2.63 µM, binding to the DNA-binding domain (IRF4-DBD) of IRF4 to block its transcriptional activity and inhibit the expression of downstream genes such as CCNC, CANX, E2F5, CMYC, HK2, and Blimp1, and inhibits the expression of MM cell cycle-related proteins CDC2, Cyclin B1, Cyclin D1, Cyclin E1, and CMYC, making it useful for studying multiple myeloma and malignant haematological diseases.

Alpinone 3-acetate showed anti-inflammatory effects and inhibited the inflammatory response in mouse ear edema models induced by 12-O-tetradecanophenol 13-acetate. Alpinone 3-acetate is a derivative of Alpinone. Alpinone is an active natural compound derived from sunflower with immunomodulatory and antiviral activities.

HEI3090 is an activator of the P2X7R receptor. This compound enhances the production of IL-18 by stimulating dendritic cells that express P2X7R, which in turn promotes the production of IFN-γ by natural killer cells and CD4T cells within tumors, triggering a sustained anti-tumor response. Additionally, HEI3090 can be used to improve the efficacy of αPD-1 therapy in non-small cell lung cancer (NSCLC).

Anti-Mouse IFN Gamma Antibody is a host Armenian Hamster-derived anti-mouse IFN gamma immunoglobulin G (IgG) inhibitor.

Peginterferon lambda-1a (BMS-914143) is a monoclonal antibody targeting IFNLR1, composed of IFNL1 conjugated to pegol [1].

hSTING activator-1 (Compound 68) is a STING agonist capable of effectively activating various human STING variants (R232, H232, HAQ), with EC50 values of 56 nM, 89 nM, and 51 nM, respectively. This compound activates the type I interferon pathway by directly binding to the STING protein and stabilizing its conformation, which leads to downstream IRF3 phosphorylation and cytokine release. hSTING activator-1 also demonstrates potential in cancer research by inhibiting fibrosarcoma tumor growth.

Paeoniflorin-6′-O-benzene sulfonate (CP-25) acts as an inhibitor of G protein-coupled receptor kinase 2 (GRK2), preventing its translocation to the cell membrane and inhibiting the JAK1/STAT3 signaling pathway. It suppresses HaCaT cell proliferation induced by IL-17A/CXCL2. In mouse models, CP-25 reduces the levels of inflammatory cytokines and chemokines such as IL-17A, IL-17F, IFN-γ, TNF-α, IL-22, IL-23, CXCL2, CXCL3, and CXCL9, thereby alleviating psoriasis induced by Imiquimod.